|
|
| | PD 117519 Basic information |
| | PD 117519 Chemical Properties |
| storage temp. | 2-8°C | | solubility | DMF: 10mg/mL; DMF:PBS (pH 7.2) (1:4): 0.2mg/mL; DMSO: 5mg/mL; Ethanol: 0.1mg/mL | | form | A solid | | InChIKey | FSKMJUWPFLDDRS-BYMDKACISA-N | | SMILES | OC[C@H]1O[C@@H](N2C3C(=C(N=CN=3)N[C@H]3C4=C(C=CC=C4)CC3)N=C2)[C@H](O)[C@@H]1O |
| | PD 117519 Usage And Synthesis |
| Uses | N6-Substituted adenosine receptor agonist; a potential antihypertensive agent. | | in vitro | PD 117519 (2-10 mg/kg; oral administration; 16-24 hours; male beagle dogs) treatment produces significant hemodynamic changes at Tmax (4 hours) follows by acute coronary vascular injury that is evident at 16 hours postdosing.Treatment with 2 or 10 mg/kg of PD 117519 produces significant increases in mean heart rate and decreases in mean indirectsystolic blood pressure at time of highest drug exposure, 4 hours postdosing. |
| | PD 117519 Preparation Products And Raw materials |
|